Atul Butte, who championed the use of big data in science and health care and inspired a generation of trainees at UC San ...

The fifth Symposium on Infectious Disease in the Immunocompromised Host convened in Seattle last month. Experts and rising ...

IMA opposes proposed integrated MBBS-BAMS course, calls it unscientific Calling the move ‘unfortunate’, it said this ‘unscientific mixing of various systems of medicines will not benefit ...

Chennai: The prospectus for MBBS/BDS admissions for 2025, available on the selection committee's official webpage, is riddled with errors, leading to .

Adding to the financial strain, MBBS interns in Punjab receive only ₹ 15,000 a month during their compulsory one-year internship. In contrast, Haryana offers a stipend of ₹ 24,300 a month, and ...

Sanofi SA (NASDAQ:SNY) on Monday agreed to acquire Blueprint Medicines Corporation (NASDAQ:BPMC). The acquisition includes a rare immunology disease medicine, Ayvakit/Ayvakyt (avapritinib ...

Surbhi Sidana, MD, MBBS, director of the Myeloma Disease Focused Group at Stanford University, provides a reintroduction to CARTITUDE-4 and insight on how this phase 3 investigation builds on ...

However, with increasing competition and high NEET cut-offs, not all students secure MBBS seats. Fortunately, there are several high-paying and rewarding career paths beyond MBBS for students from ...

Sundar Jagannath, MBBS, highlights long-term follow-up data from the phase 1b/2 CARTITUDE-1 trial, showing durable responses and potential cures with ciltacabtagene autoleucel in patients with ...

Sanofi will acquire Blueprint Medicines for up to $9.5 billion, gaining Ayvakit and a promising immunology pipeline, including BLU-808 and elenestinib.